Centessa Pharmaceuticals plc (CNTA) has priced its underwritten public offering of 11.63 million American Depositary Shares ("ADSs"), each representing one ordinary share, at $21.50 per ADS.
This clinical-stage biopharmaceutical company is pioneering a new class of therapies targeting orexin receptor 2 (OX2R) for neurological, neurodegenerative, and neuropsychiatric disorders.
The offering, which is scheduled to close on or about November 14, 2025, is expected to generate gross proceeds of approximately $250 million before deducting underwriting discounts and expenses.
The underwriters have a 30-day option to purchase up to an additional 1.74 million ADSs at the public offering price, less underwriting discounts and commissions.
CNTA has traded in the range of $9.60 - $25.42 in the last 1 year. The stock closed yesterday's trading at $22.54, up 0.94%.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.